
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : KCNC1 Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Variants of the KCNC1 gene impact Kv3.1 potassion channel function, resulting in neurodevelopmental diorders which can include progressive myolclonic epilepsy (PME) and developmental epileptic encephalopathy (DEE).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 07, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : KCNC1 Foundation
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Recipient : Bioqube Ventures
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration, Bioqube and Metrion will advance a lead series of previously identified highly potent and selective small molecule inhibitors of the human Kv1.3 potassium ion channel to enable further development.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Recipient : Bioqube Ventures
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Sosei Heptares
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to demonstrate the potential of Sosei Heptares’ SBDD technologies to address disease-associated ion channels and work towards establishing a leadership position in this area, in a similar way that it has done for G protein-couple...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 01, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Sosei Heptares
Deal Size : Undisclosed
Deal Type : Collaboration

Details : The collaboration focuses on the discovery of novel selective small molecular modulators of a specific two-pore potassium ion target, identified as likely to be involved in neurological pathogenesis, and has now progressed to the hit-to-lead optimization...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 18, 2021
